Keifei Femaric Letrozole Loose 30 Tablets

Femaric — Letrozole

Pharmaceutical Form: Oral Tablets | Classification: Nonsteroidal Aromatase Inhibitor

Presentation

Each 2.5mg tablet is light yellow, film-coated, round concave, with KF wording imprinted on one side. Supplied in plastic blister packs (3 strips × 10 tablets = 30 tablets per box). Each box includes a 10-digit authentication code to ensure authenticity.

About Femaric (Letrozole)

Letrozole is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also prescribed as:

• Extended adjuvant therapy after 5 years of tamoxifen treatment.
• First-line treatment for hormone receptor-positive or metastatic breast cancer in postmenopausal women.
• Treatment of advanced breast cancer in women with disease progression following anti-estrogen therapy.

Letrozole is a nonsteroidal aromatase inhibitor used in hormonally responsive breast cancer. Estrogens are produced by converting androgens via the aromatase enzyme. Letrozole works by competitively binding to the haem group of the cytochrome P450 aromatase enzyme, blocking the conversion of androgens to estrogens and significantly reducing plasma estrogen levels.

Contraindications

Femaric (Letrozole) should not be used in patients with:

• Known hypersensitivity to Letrozole, excipients, or other aromatase inhibitors.
• Pregnancy or lactation.
• Premenopausal status.
• Severe hepatic dysfunction.